Literature DB >> 12145245

Is insulin sensitivity a causal intermediate in the relationship between alcohol consumption and carotid atherosclerosis?: the insulin resistance and atherosclerosis study.

Daniel E Cooper1, David C Goff, Ronny A Bell, Dan Zaccaro, Elizabeth J Mayer-Davis, Andrew J Karter.   

Abstract

OBJECTIVE: A J-shaped association has been demonstrated between alcohol consumption and atherosclerosis. Insulin resistance, also a risk factor for atherosclerosis, has been shown to have a similar J-shaped association with alcohol intake. This raises the question of whether insulin sensitivity (S(I)) is a causal intermediate in the alcohol-atherosclerosis relationship. RESEARCH DESIGN AND METHODS: The Insulin Resistance Atherosclerosis Study was a multicenter cohort study designed to investigate relationships among S(I), risk factors for cardiovascular disease, and carotid artery atherosclerosis. Using regression analysis, we tested whether adjustment for S(I) attenuated the alcohol-atherosclerosis relationship observed at baseline.
RESULTS: A J-shaped association was observed between alcohol consumption and common carotid artery intimal medial thickness. The protective aspect of the alcohol-atherosclerosis relationship was attenuated by 25% after the adjustment for S(I). However, an interaction was observed between alcohol consumption and glucose tolerance (GT) status. In comparison with never drinkers, all levels of alcohol consumption were associated with less atherosclerosis in participants with normal GT status. Participants with impaired GT status (but not diabetes) demonstrated a J-shaped alcohol-atherosclerosis association. All levels of alcohol consumption were associated with more atherosclerosis in participants with diabetes.
CONCLUSIONS: S(I) may be a causal intermediate at protective levels of alcohol intake, but an alcohol-GT interaction precluded a definitive conclusion. Moderate alcohol consumption may increase the risk of atherosclerosis in people with diabetes. These findings contrast with previous reports and do not support current recommendations regarding moderate alcohol consumption in people with diabetes. More research is needed to clarify this issue.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12145245     DOI: 10.2337/diacare.25.8.1425

Source DB:  PubMed          Journal:  Diabetes Care        ISSN: 0149-5992            Impact factor:   19.112


  6 in total

1.  Long-term ethanol exposure inhibits glucose transporter 4 expression via an AMPK-dependent pathway in adipocytes.

Authors:  Li Feng; Yong-feng Song; Qing-bo Guan; Hong-jun Liu; Bo Ban; Hai-xin Dong; Xiao-lei Hou; Kok-onn Lee; Ling Gao; Jia-jun Zhao
Journal:  Acta Pharmacol Sin       Date:  2010-02-22       Impact factor: 6.150

2.  Muscle hematoma: a critically important complication of alcoholic liver cirrhosis.

Authors:  Chiyo Sugiyama; Akifumi Akai; Noriyoshi Yamakita; Tsuneko Ikeda; Keigo Yasuda
Journal:  World J Gastroenterol       Date:  2009-09-21       Impact factor: 5.742

3.  Alcohol consumption and diabetes risk in the Diabetes Prevention Program.

Authors:  Jill P Crandall; Sarit Polsky; Andrea A Howard; Leigh Perreault; George A Bray; Elizabeth Barrett-Connor; Janet Brown-Friday; Tracy Whittington; Sandra Foo; Yong Ma; Sharon L Edelstein
Journal:  Am J Clin Nutr       Date:  2009-07-29       Impact factor: 7.045

4.  Meta-analysis of the relationship between alcohol consumption and coronary heart disease and mortality in type 2 diabetic patients.

Authors:  L L J Koppes; J M Dekker; H F J Hendriks; L M Bouter; R J Heine
Journal:  Diabetologia       Date:  2006-02-04       Impact factor: 10.122

5.  Iliopsoas muscle hematoma secondary to alcoholic liver cirrhosis.

Authors:  Suguru Yamashita; Nobutaka Tanaka; Yukihiro Nomura; Takuya Miyahara; Takatoshi Furuya
Journal:  Case Rep Gastroenterol       Date:  2012-11-08

6.  Obesity and accumulation of subcutaneous adipose tissue are poor prognostic factors in patients with alcoholic liver cirrhosis.

Authors:  Akira Sakamaki; Kunihiko Yokoyama; Kyutaro Koyama; Shinichi Morita; Hiroyuki Abe; Kenya Kamimura; Masaaki Takamura; Shuji Terai
Journal:  PLoS One       Date:  2020-11-17       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.